Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer[1].
Paclitaxel is conjugated to a brain peptide vector, Angiopep-2, to provide a paclitaxel- Angiopep-2 conjugate named ANG1005. ANG1005 enters the brain to a greater extent than paclitaxel and bypasses the P-gp. ANG1005 has an antineoplastic potency similar to that of paclitaxel against human cancer cell lines[1].
ANG1005 administration leads to a significant increase in the survival of mice with intracerebral implantation of U87 MG glioblastoma cells or NCI-H460 lung carcinoma cells[1].
[1]. A RÉgina, et al. Antitumour Activity of ANG1005, a Conjugate Between Paclitaxel and the New Brain Delivery Vector Angiopep-2. Br J Pharmacol. 2008 Sep;155(2):185-97.